This report provides a comprehensive overview of the size of the regenerative medicine market, segmentation of the market (stem cells, tissue engineering and CAR-T therapy), key players and the vast potential of therapies that are in clinical trials. Kelly Scientific analysis indicates that the global regenerative medicine market was worth $18.9 billion in 2016 and will grow to over $66 billion by 2022, with a CAGR of 23.3% between this time frame. Within this market, the stem cell industry will grow significantly at a CAGR of over x% and reach $x billion by 2022. Tissue engineering is forecast to grow at a CAGR of x% to 2022 and potentially reach $x billion. This report describes the evolution of such a huge market in 15 chapters supported by over 350 tables and figures in 680 pages.
• An overview of regenerative medicine that includes: stem cells, allogenic and autogenic cells, umbilical cord blood banking, tissue engineering and CAR T therapies.
• Global regenerative medicine market, global breakdown, application breakdown and leading market players
• Detailed account of the stem cell industry market by geography, indication and company profiles
• Profiles, marketed/pipeline products, financial analysis and business strategy of the major companies in this space
• Focus on current trends, business environment, pipeline products, clinical trials, and future market forecast for regenerative medicine
• Insight into the challenges faced by stakeholders, particularly about the success vs. failure ratios in developing regenerative medicine drugs and therapies.
• Insight into the biobanking industry globally and its impact on the overall market
• Description and data for the prevalence of disease types that are addressed by regenerative medicine, stem cells, tissue engineering and CAR-T therapies
• Financial market forecast through 2022 with CAGR values of all market segments outlined in the objective
• SWOT analysis of the global market
• Geographical analysis and challenges within key topographies including the USA, Japan, South Korea, China and Europe
Countries Covered
Global, USA, Europe, UK, Japan, South Korea, Singapore, Asia/Pacific, ROC
Companies Mentioned
Astellas Institute for Regenerative Medicine (Ocata Therapeutics)
AstraZeneca
Athersys
Baxter International (Baxalta, Shire)
Bayer
Caladrius Biosciences (NeoStem)
Celgene
CHA Biotech
Chimerix
Cynata Therapeutics
Cytori Therapeutics
Eisai
Genzyme (Sanofi)
GSK
Janssen
InCyte Corp
MedImmune
MEDIPOST
Merck
Mesoblast
Millennium Pharmaceutical
NuVasive
Osiris Therapeutics
Plasticell
Pluristem Therapeutics
Pfizer
SanBio Current Stem Cell Trials
Seattle Genetics Current Stem Cell Trials
StemCells Inc
STEMCELL Technologies
Takara Bio
Teva Current Stem Cell Trials
Tigenix